Schizophrenia and Bipolar I Disorder
Schizophrenia and Bipolar I Disorder: Understanding Patient Needs to Guide Targeted Treatment Approaches
Duration: 60 minutes
Presented on: April 26, 2023
living with bipolar
René Kahn, MD, PhD
René Kahn, MD, PhD
Esther and Joseph Klingenstein Professor & Chair, Department of Psychiatry and Behavioral Health SystemRené Kahn, MD, is currently the Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai. In 1993, Dr. Kahn was Chair of Psychiatry at the University Hospital in Utrecht, Netherlands and went on to lead the Brain Center Rudolf Magnus, which combines research in basic neuroscience, psychiatry, and neurology. In 2018, Dr. Kahn was knighted in the Netherlands. He has published over 1000 research papers with a Web of Science H index of 126, and has been continuously funded for over 25 years by NIMH, the EU, the Stanley Foundation, and other organizations. Dr. Kahn has served on neuroscience grant review boards in the Netherlands, United Kingdom, and Germany. Furthermore, he received several honors, one being the lifetime achievement award of the Netherlands Psychiatric Association.
Christoph Correll, MD
Christoph Correll, MD
Professor and Chair, Department of Child and Adolescent PsychiatryChristoph Correll, MD, is Professor of Psychiatry at Zucker School of Medicine at Hofstra/Northwell in New York as well as Professor and Chair of the Department of Child and Adolescent Psychiatry at Charité University Medicine in Berlin, Germany. Dr. Correll’s interests focus on the identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-analyses, and the interface between physical health and mental health. He has authored or co-authored over 800 journal articles and received over 40 research awards for his work. Since 2014, the start of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.
patient in long-term recovery
Schizophrenia and Bipolar I Disorder:
Understanding Patient Needs to Guide Targeted Treatment Approaches
ACKNOWLEDGEMENTThis activity is supported by educational grants from Alkermes, Inc. and Indivior Inc.
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
ENDURING CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATIONEnduring Material
The enduring material will be available from April 26, 2023, to April 26, 2024.
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
- Discuss persistent real-world challenges faced by patients living with schizophrenia or bipolar I disorder
- Consider patient- and treatment-related factors when formulating treatment plans for patients living with schizophrenia or bipolar I disorder
- Evaluate clinical evidence for newly approved and emerging agents in schizophrenia and bipolar I disorder management
TARGET AUDIENCEThe target audience for the activity are psychologists, psychiatrists, primary care physicians, nurse practitioners, physician assistants in psychiatry and primary care, and other mental health specialists.
ESTIMATED TIME TO COMPLETE1 hour
METHOD OF PARTICIPATIONThere are no fees to participate in this activity. To participate in the activity, go to www.PsychiatryCareLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTERESTPostgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Name of Faculty or Presenter Reported Financial Relationship René S. Kahn, MD, PhD
Esther and Joseph Klingenstein Professor & Chair
Department of Psychiatry and Behavioral Health System
Icahn School of Medicine at Mount Sinai
Consultant/Advisory Board: Alkermes, Merck, Sunuvion Christoph U. Correll, MD
Professor of Psychiatry
Zucker School of Medicine at Hofstra/Northwell
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine, Berlin, Germany
Grant/Research Support: Janssen, Takeda
Honoraria for non-CME: AbbVie, Angelini, Aristo, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Lundbeck, Mitsubishi Tanabe Pharma, Mylan, Otsuka, Recordati, Seqirus, Sunovion, Takeda, Viatris.
Consultant/Advisory Board: AbbVie, Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Gedeon Richter, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Mindpax, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris.
Non-Mutual funds Stock Ownership/Stock options: Stock option holder only of Cardio Diagnostics, Mindpax, LB Pharma and Quantic
Royalties paid to you: UpToDate
The PIM planners and managers have nothing to disclose. The PlatformQ Health Education, LLC planners and others have nothing to disclose.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support:
Please contact the Postgraduate Institute for Medicine at email@example.com.
For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive.com at 877-394-1306 or at Support@PsychiatryCareLive.com.